No profile data available.
Boundless Bio, Inc. (BOLD) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 28 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$58.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $57.55 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Boundless Bio reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$57.55 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Maia Biotechnology, Inc. (MAIA), Oncolytics Biotech Inc. (ONCY), Xilio Therapeutics, Inc. (XLO), Elicio Therapeutics, Inc. (ELTX).